tiprankstipranks
Advertisement
Advertisement
iBio Highlights Promising New Preclinical Obesity Antibody Data
PremiumCompany AnnouncementsiBio Highlights Promising New Preclinical Obesity Antibody Data
2M ago
iBio announces new preclinical data from IBIO-610 study
Premium
The Fly
iBio announces new preclinical data from IBIO-610 study
2M ago
iBio initiated with an Outperform at Raymond James
Premium
The Fly
iBio initiated with an Outperform at Raymond James
3M ago
Validating iBio’s Antibody Platform: Buy Rating Driven by IBIO-600’s Differentiated Obesity Profile and Long-Acting Myostatin Inhibition
PremiumRatingsValidating iBio’s Antibody Platform: Buy Rating Driven by IBIO-600’s Differentiated Obesity Profile and Long-Acting Myostatin Inhibition
5M ago
iBio Advances to Clinical Stage With IBIO-600 Trial
Premium
Company Announcements
iBio Advances to Clinical Stage With IBIO-600 Trial
5M ago
iBio receives regulatory clearance to initiate IBIO-600 trial in Australia
Premium
The Fly
iBio receives regulatory clearance to initiate IBIO-600 trial in Australia
5M ago
iBio to provide update on cardiopulmonary program
PremiumThe FlyiBio to provide update on cardiopulmonary program
6M ago
Buy Rating on iBio Driven by Promising IBIO-610 Obesity Data and Favorable Risk-Reward Profile
Premium
Ratings
Buy Rating on iBio Driven by Promising IBIO-610 Obesity Data and Favorable Risk-Reward Profile
6M ago
iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential
Premium
Company Announcements
iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100